Please use this identifier to cite or link to this item: https://doi.org/10.3390/biomedicines7030053
DC FieldValue
dc.titleA brief overview of the antitumoral actions of leelamine
dc.contributor.authorMerarchi, M.
dc.contributor.authorJung, Y.Y.
dc.contributor.authorFan, L.
dc.contributor.authorSethi, G.
dc.contributor.authorAhn, K.S.
dc.date.accessioned2021-12-09T03:02:17Z
dc.date.available2021-12-09T03:02:17Z
dc.date.issued2019
dc.identifier.citationMerarchi, M., Jung, Y.Y., Fan, L., Sethi, G., Ahn, K.S. (2019). A brief overview of the antitumoral actions of leelamine. Biomedicines 7 (3) : 53. ScholarBank@NUS Repository. https://doi.org/10.3390/biomedicines7030053
dc.identifier.issn2227-9059
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/209941
dc.description.abstractFor the last couple of decades, natural products, either applied singly or in conjunction with other cancer therapies including chemotherapy and radiotherapy, have allowed us to combat different types of human cancers through the inhibition of their initiation and progression. The principal sources of these useful compounds are isolated from plants that were described in traditional medicines for their curative potential. Leelamine, derived from the bark of pine trees, was previously reported as having a weak agonistic effect on cannabinoid receptors and limited inhibitory effects on pyruvate dehydrogenase kinases (PDKs). It has been reported to possess a strong lysosomotropic property; this feature enables its assembly inside the acidic compartments within a cell, such as lysosomes, which may eventually hinder endocytosis. In this review, we briefly highlight the varied antineoplastic actions of leelamine that have found implications in pharmacological research, and the numerous intracellular targets affected by this agent that can effectively negate the oncogenic process. © 2019 by the authors.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2019
dc.subjectLeelamine
dc.subjectMalignancies
dc.subjectMolecular mechanisms
dc.subjectPreclinical models
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.3390/biomedicines7030053
dc.description.sourcetitleBiomedicines
dc.description.volume7
dc.description.issue3
dc.description.page53
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_biomedicines7030053.pdf789.14 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons